Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abbott’s PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
New PLEX-ID system and three clinical tests introduced in the European union.

Abbott has announced that it has obtained CE Marking in the European Union to market its rapid, high-throughput PLEX-ID™ instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

PLEX-ID, which is based on molecular diagnostic technologies, addresses a significant unmet need for rapid detection and identification of a broad range of microbes that cause infections in patients.

It provides results in less than eight hours instead of the days or even weeks required for traditional culture methods. The unique advantage of the system is the ability to characterize a very wide range of microorganisms directly from clinical specimens, thus minimizing both the amount of time and laboratory work required to provide physicians important information they can use to best tailor treatment for the patient.

"Ensuring that patients receive the most appropriate antimicrobial therapy as rapidly as possible has the potential to reduce inappropriate antibiotic prescribing, and help to reduce or slow the development of resistant bacterial strains," said Jacques Schrenzel, M.D., head of the Bacteriological Laboratory, University Hospital Geneva in Geneva, Switzerland.

"PLEX-ID is the only available diagnostic technology that is capable of identifying a wide range of bacteria, viruses, fungi, and certain parasites in hours," said Murthy Simhambhatla, Ph.D., head of Abbott’s Ibis Biosciences business.

Simhambhatla continued, "The introduction of the PLEX-ID provides physicians and laboratorians a revolutionary new platform for the rapid etiologic identification of a wide variety of pathogens in patients."

Assays to Rapidly Identify Pathogens in Seriously Ill Patients
Research presented in several global scientific venues has shown that the PLEX-ID technology offers rapid detection and characterization of a wide range of pathogens, which can be extremely important in patients who have an impaired immune system such as those with cancer or patients who have had a transplant.

The PLEX-ID Viral IC Spectrum assay is designed to detect and identify 11 viral families with more than 250 species of important systemic viral pathogens, including herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human adenovirus, human enterovirus, BK and JC polyomaviruses, and parvovirus B19, directly from plasma specimens.

These viruses represent a significant threat to vulnerable patients with weakened immune systems. Systemic viral infections are a serious problem, occurring in one out of every six transplant patients.

Earlier detection can enable physicians to act more quickly to manage the patient’s infection.

The PLEX-ID BAC Spectrum BC assay can detect and identify nearly 400 species of bacteria, and also can detect the presence of genetic markers that determine bacterial resistance to certain antibiotics.

In addition, the test can identify and classify species of Candida, a fungus that is an increasingly common cause of serious systemic infections.

The assay performs this analysis on blood culture positive specimens. Abbott plans to introduce a modified version of the assay in Europe later this year which is designed to analyze the blood sample immediately after it reaches the lab rather than having to first wait for the organism to grow in culture.

The PLEX-ID Flu assay is intended for detection and identification of known influenza A viruses, newly emerging influenza A strains, and influenza B.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abbott Molecular Receives EUA for Zika MDx
The test is authorized to detect Zika virus RNA in blood plasma and serum as well as urine samples and can provide results within five to seven hours.
Saturday, December 03, 2016
Abbott Completes Acquisition of Topera, Inc.
Company acquire all outstanding equity of Topera for $250 million upfront.
Tuesday, January 06, 2015
Abbott to Acquire Veropharm
The acquisition of the Russian pharmaceutical manufacturer is in keeping with the long term commitment to provide healthcare products to Russian patients.
Monday, June 23, 2014
Partners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti
Facility produces first shipments of locally sourced, therapeutic food to treat severe malnutrition in children.
Monday, November 11, 2013
Abbott Completes Separation of Research-Based Pharmaceuticals Business
Set to deliver industry-leading growth, expanding margins and strong cash flow.
Monday, January 07, 2013
Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval
HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants.
Thursday, October 04, 2012
Abbott to Collaborate with Astellas Pharma
The companies will collaborate in a Phase 3 clinical trial for ASP0113, an investigational vaccine for preventing cytomegalovirus reactivation in transplant patients.
Thursday, September 06, 2012
Leading Agent in the Treatment of Psosiasis
Abbott/Eisai's Humira has emerged on top with major-market sales of more than $1.4 billion in 2011.
Tuesday, August 07, 2012
Abbott Licenses Prostate Cancer Biomarkers
The exclusive license from Stanford University for several novel biomarkers could help develop a molecular diagnostic test that differentiates aggressive from nonaggressive prostate cancer.
Wednesday, April 18, 2012
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Abbott Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
Thursday, March 22, 2012
Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories
FDA will begin implementing the software-based LIMS as part of the agency's initiative to enhance FDA testing laboratories by managing complex processes and analysing the vast amount of information generated.
Thursday, January 19, 2012
Abbott and University of Illinois Establish Center for Nutrition, Learning and Memory
The companies have established the first-ever multi-disciplinary nutrition and cognition research center,. The Center for Nutrition, Learning, and Memory will lead directed and solicited research on the impact of nutrition on learning and memory in the human brain.
Tuesday, December 20, 2011
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Wednesday, December 14, 2011
Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test
Companion diagnostic tests identify specific DNA sequences for cancer immunotherapy antigen.
Tuesday, November 29, 2011
FDA Approves First Supplemental Test for Chagas Disease
The U.S. Food and Drug Administration have approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to T. cruzi, which causes Chagas disease, a serious and potentially fatal parasitic infection.
Monday, November 21, 2011
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!